A 12-week open-label, multicenter study evaluating the safety and patient-reported efficacy of sodium oxybate in patients with narcolepsy and cataplexy

Sleep Medicine

Volumn 16, Issue 1, 2015, Pages 52-58

  Mamelak, Mortimer ^a   Swick, Todd ^b   Emsellem, Helene ^c,d   Montplaisir, Jacques ^e   Lai, Chinglin ^f   Black, Jed ^f,g  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d Center for Sleep and Wake Disorders   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f JAZZ PHARMACEUTICALS   (United States)

^g STANFORD UNIVERSITY   (United States)

Author keywords

Attention; Cataplexy; Efficacy; Excessive daytime sleepiness; Narcolepsy; Open label; Patient reported outcomes; Safety; Sleep quality; Sodium oxybate

Indexed keywords

OXYBATE SODIUM; CENTRAL DEPRESSANT AGENT;

ABDOMINAL PAIN; ANXIETY DISORDER; ARTICLE; BLOATING; CATAPLEXY; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENURESIS; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NARCOLEPSY; NAUSEA; OTITIS MEDIA; PAIN; PSYCHOSIS; SELF REPORT; SINUSITIS; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING; ADULT; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DRUG ADMINISTRATION; MIDDLE AGED; OUTCOME ASSESSMENT; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SYMPTOM ASSESSMENT;

ADJUVANTS, ANESTHESIA; ADULT; CATAPLEXY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; SODIUM OXYBATE; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 84921433466     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2014.10.004     Document Type: Article

References (29)

1. Rosenberg R., Kim A.Y. The AWAKEN Survey: knowledge of narcolepsy among physicians and the general population. Postgrad Med 2014, 126:78-86.
2. Thorpy M.J., Krieger A.C. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med 2014, 15:502-507.
3. Nishino S., Deguzman C., Yamadera W., Chiba S., Kanbayashi T. Neurochemistry and biomarkers of narcolepsy and other primary and secondary hypersomnias. Sleep Med Clin 2012, 7:233-248.
4. De la Herran-Arita A.K., Garcia-Garcia F. Narcolepsy as an immune-mediated disease. Sleep Disord 2014, 2014:792687.
5. Jennum P., Ibsen R., Knudsen S., Kjellberg J. Comorbidity and mortality of narcolepsy: a controlled retro- and prospective national study. Sleep 2013, 36:835-840.
6. Ohayon M.M. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med 2013, 14:488-492.
7. Daniels E., King M.A., Smith I.E., Shneerson J.M. Health-related quality of life in narcolepsy. J Sleep Res 2001, 10:75-81.
8. Jennum P., Ibsen R., Petersen E.R., Knudsen S., Kjellberg J. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med 2012, 13:1086-1093.
9. Campbell A.J., Signal T.L., O'Keeffe K.M., Bakker J.P. Narcolepsy in New Zealand: pathway to diagnosis and effect on quality of life. N Z Med J 2011, 124:51-61.
10. Dodel R., Peter H., Spottke A., Noelker C., Althaus A., Siebert U., et al. Health-related quality of life in patients with narcolepsy. Sleep Med 2007, 8:733-741.
11. Black J., Reaven N.L., Funk S., McGaughey K., Ohayon M.M., Guilleminault C., et al. The burden of narcolepsy disease (BOND) study: healthcare utilization and cost findings. Sleep Med 2014, 15:522-529.
12. American Academy of Sleep Medicine The international classification of sleep disorders, revised: diagnostic and coding manual 2005, American Academy of Sleep Medicine, Rochester, MN. 2nd ed.
13. Baumann C.R., Mignot E., Lammers G.J., Overeem S., Arnulf I., Rye D., et al. Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep 2014, 37:1035-1042.
14. Roth T., Dauvilliers Y., Mignot E., Montplaisir J., Paul J., Swick T., et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med 2013, 9:955-965.
15. Dauvilliers Y., Montplaisir J., Molinari N., Carlander B., Ondze B., Besset A., et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001, 57:2029-2033.
16. Okun M.L., Lin L., Pelin Z., Hong S., Mignot E. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002, 25:27-35.
17. Morgenthaler T.I., Kapur V.K., Brown T., Swick T.J., Alessi C., Aurora R.N., et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007, 30:1705-1711.
18. Xyrem (sodium oxybate) oral solution [prescribing information] 2014, Jazz Pharmaceuticals, Inc, Palo Alto, CA.
19. Mamelak M., Black J., Montplaisir J., Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004, 27:1327-1334.
20. Black J., Pardi D., Hornfeldt C.S., Inhaber N. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med 2009, 10:829-835.
21. Black J., Pardi D., Hornfeldt C.S., Inhaber N. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med 2010, 6:596-602.
22. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002, 25:42-49. The US Xyrem Multi-Center Study Group.
23. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005, 1:391-397. Xyrem International Study Group.
24. Black J., Houghton W.C. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006, 29:939-946.
25. Naumann A., Bellebaum C., Daum I. Cognitive deficits in narcolepsy. J Sleep Res 2006, 15:329-338.
26. Bayard S., Croisier Langenier M., Cochen De Cock V., Scholz S., Dauvilliers Y. Executive control of attention in narcolepsy. PLoS ONE 2012, 7:e33525.
27. Scharf M.B., Brown D., Woods M., Brown L., Hirschowitz J. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. J Clin Psychiatry 1985, 46:222-225.
28. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003, 26:31-35. U.S. Xyrem Multicenter Study Group.
29. Lammers G.J., Arends J., Declerck A.C., Ferrari M.D., Schouwink G., Troost J. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 1993, 16:216-220.